Anzeige
Mehr »
Sonntag, 05.07.2026 - Börsentäglich über 12.000 News
Milliardenkonkurrenten im Visier: Dieser KI-Wert gewinnt namhafte Großkunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P723 | ISIN: KYG674111011 | Ticker-Symbol: 5DG
Frankfurt
03.07.26 | 17:15
0,525 Euro
+9,83 % +0,047
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
OCUMENSION THERAPEUTICS Chart 1 Jahr
5-Tage-Chart
OCUMENSION THERAPEUTICS 5-Tage-Chart
RealtimeGeldBriefZeit
0,5500,58504.07.
0,5250,61003.07.

Aktuelle News zur OCUMENSION THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoOCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-502 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION1
DiOCUMENSION-B (01477): RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY AND CHANGE IN AUTHORIZED REPRESENTATIVE1
DiOCUMENSION-B (01477): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION-
DiOCUMENSION-B (01477): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026 AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE ...-
08.06.OCUMENSION-B (01477): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 30, 20261
08.06.OCUMENSION-B (01477): NOTICE OF ANNUAL GENERAL MEETING2
OCUMENSION THERAPEUTICS Aktie jetzt für 0€ handeln
08.06.OCUMENSION-B (01477): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS AND PROPOSED ...1
28.05.OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-802-
12.05.OCUMENSION-B (01477): GRANTS OF OPTIONS AND AWARDS-
28.04.OCUMENSION-B (01477): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS1
28.04.OCUMENSION-B (01477): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS-
28.04.OCUMENSION-B (01477): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT1
28.04.OCUMENSION-B (01477): 2025 ANNUAL REPORT-
30.03.OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-211-
26.03.OCUMENSION-B (01477): RETIREMENT AND PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR-
26.03.OCUMENSION-B (01477): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025-
10.03.OCUMENSION-B (01477): DATE OF BOARD MEETING1
19.01.OCUMENSION-B (01477): VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE REAL-WORLD STUDY OF OT-703 IN HAINAN BOAO1
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1